Reassessing evidence of Moon–Earth dynamics from tidal bundles at 3.2 Ga (Moodies Group, Barberton Greenstone Belt, South Africa)

Past orbital parameters of the Moon are difficult to reconstruct from geological records because relevant data sets of tidal strata are scarce or incomplete. The sole Archean data point is from the Moodies Group (ca 3.22 Ga) of the Barberton Greenstone Belt, South Africa. From the time-series analysis of tidal bundles from a well-exposed subaqueous sand wave of this unit, Eriksson and Simpson (Geology, 28, 831) suggested that the Moon’s anomalistic month at 3.2 Ga was closer to 20 days than the present 27.5 days. This is in apparent accordance with models of orbital mechanics which place the Archean Moon in a closer orbit with a shorter period, resulting in stronger tidal action. Although this study’s detailed geological mapping and section measuring of the site confirmed that the sandstone bed in question is likely a migrating dune, the presence of angular mud clasts, channel-margin slumps, laterally aggrading channel fills and bidirectional paleocurrents in overlying and underlying beds suggests that this bedform was likely located in a nearshore channel near lower-intertidal flats and subtidal estuarine bars; it thus carries risk of incomplete preservation. Repeated measurements of foreset thicknesses along the published traverse, measured perpendicular to bedding, failed to show consistent spectral peaks. Larger data sets acquired along traverses measured parallel to bedding along the 20.5 m wide exposure are affected by minor faulting, uneven outcrop weathering, changing illumination, weather, observer bias and show a low reproducibility. The most robust measurements herein confirm the periodicity peak of approximately 14 in the original data of Eriksson and Simpson (Geology, 28, 831). Because laminae may have been eroded, the measurements may represent a lower bound of about 28 lunar days per synodic month. This estimate agrees well with Earth–Moon dynamic models which consider the conservation of angular momentum and place the Archaean Moon in a lower orbit around a faster-spinning Earth

Reassessing evidence of Moon–Earth dynamics from tidal bundles at 3.2 Ga (Moodies Group, Barberton Greenstone Belt, South Africa)

Past orbital parameters of the Moon are difficult to reconstruct from geological records because relevant data sets of tidal strata are scarce or incomplete. The sole Archean data point is from the Moodies Group (ca 3.22 Ga) of the Barberton Greenstone Belt, South Africa. From the time-series analysis of tidal bundles from a well-exposed subaqueous sand wave of this unit, Eriksson and Simpson (Geology, 28, 831) suggested that the Moon’s anomalistic month at 3.2 Ga was closer to 20 days than the present 27.5 days. This is in apparent accordance with models of orbital mechanics which place the Archean Moon in a closer orbit with a shorter period, resulting in stronger tidal action. Although this study’s detailed geological mapping and section measuring of the site confirmed that the sandstone bed in question is likely a migrating dune, the presence of angular mud clasts, channel-margin slumps, laterally aggrading channel fills and bidirectional paleocurrents in overlying and underlying beds suggests that this bedform was likely located in a nearshore channel near lower-intertidal flats and subtidal estuarine bars; it thus carries risk of incomplete preservation. Repeated measurements of foreset thicknesses along the published traverse, measured perpendicular to bedding, failed to show consistent spectral peaks. Larger data sets acquired along traverses measured parallel to bedding along the 20.5 m wide exposure are affected by minor faulting, uneven outcrop weathering, changing illumination, weather, observer bias and show a low reproducibility. The most robust measurements herein confirm the periodicity peak of approximately 14 in the original data of Eriksson and Simpson (Geology, 28, 831). Because laminae may have been eroded, the measurements may represent a lower bound of about 28 lunar days per synodic month. This estimate agrees well with Earth–Moon dynamic models which consider the conservation of angular momentum and place the Archaean Moon in a lower orbit around a faster-spinning Earth

Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration

Ischemic stroke is the second leading cause of death worldwide. Only one moderately effective therapy exists, albeit with contraindications that exclude 90% of the patients. This medical need contrasts with a high failure rate of more than 1,000 pre-clinical drug candidates for stroke therapies. Thus, there is a need for translatable mechanisms of neuroprotection and more rigid thresholds of relevance in pre-clinical stroke models. One such candidate mechanism is oxidative stress. However, antioxidant approaches have failed in clinical trials, and the significant sources of oxidative stress in stroke are unknown. We here identify NADPH oxidase type 4 (NOX4) as a major source of oxidative stress and an effective therapeutic target in acute stroke. Upon ischemia, NOX4 was induced in human and mouse brain. Mice deficient in NOX4 (Nox4(-/-)) of either sex, but not those deficient for NOX1 or NOX2, were largely protected from oxidative stress, blood-brain-barrier leakage, and neuronal apoptosis, after both transient and permanent cerebral ischemia. This effect was independent of age, as elderly mice were equally protected. Restoration of oxidative stress reversed the stroke-protective phenotype in Nox4(-/-) mice. Application of the only validated low-molecular-weight pharmacological NADPH oxidase inhibitor, VAS2870, several hours after ischemia was as protective as deleting NOX4. The extent of neuroprotection was exceptional, resulting in significantly improved long-term neurological functions and reduced mortality. NOX4 therefore represents a major source of oxidative stress and novel class of drug target for stroke therapy

International Journal of Cancer / Synergistic crosstalk of hedgehog and interleukin6 signaling drives growth of basal cell carcinoma

Persistent activation of hedgehog (HH)/GLI signaling accounts for the development of basal cell carcinoma (BCC), a very frequent nonmelanoma skin cancer with rising incidence. Targeting HH/GLI signaling by approved pathway inhibitors can provide significant therapeutic benefit to BCC patients. However, limited response rates, development of drug resistance, and severe side effects of HH pathway inhibitors call for improved treatment strategies such as rational combination therapies simultaneously inhibiting HH/GLI and cooperative signals promoting the oncogenic activity of HH/GLI. In this study, we identified the interleukin6 (IL6) pathway as a novel synergistic signal promoting oncogenic HH/GLI via STAT3 activation. Mechanistically, we provide evidence that signal integration of IL6 and HH/GLI occurs at the level of cisregulatory sequences by cobinding of GLI and STAT3 to common HHIL6 target gene promoters. Genetic inactivation of Il6 signaling in a mouse model of BCC significantly reduced in vivo tumor growth by interfering with HH/GLIdriven BCC proliferation. Our genetic and pharmacologic data suggest that combinatorial HHIL6 pathway blockade is a promising approach to efficiently arrest cancer growth in BCC patients.(VLID)301234

A time-resolved proteomic and prognostic map of COVID-19

COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

BACKGROUND: Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of COVID-19 are limited. METHODS: In this international randomised, double-blind, placebo-controlled trial, hospitalised patients with COVID-19 who had been symptomatic for up to 12 days and did not have acute end-organ failure were randomly assigned (1:1) to receive either hIVIG or an equivalent volume of saline as placebo, in addition to remdesivir, when not contraindicated, and other standard clinical care. Randomisation was stratified by site pharmacy; schedules were prepared using a mass-weighted urn design. Infusions were prepared and masked by trial pharmacists; all other investigators, research staff, and trial participants were masked to group allocation. Follow-up was for 28 days. The primary outcome was measured at day 7 by a seven-category ordinal endpoint that considered pulmonary status and extrapulmonary complications and ranged from no limiting symptoms to death. Deaths and adverse events, including organ failure and serious infections, were used to define composite safety outcomes at days 7 and 28. Prespecified subgroup analyses were carried out for efficacy and safety outcomes by duration of symptoms, the presence of anti-spike neutralising antibodies, and other baseline factors. Analyses were done on a modified intention-to-treat (mITT) population, which included all randomly assigned participants who met eligibility criteria and received all or part of the assigned study product infusion. This study is registered with ClinicalTrials.gov, NCT04546581. FINDINGS: From Oct 8, 2020, to Feb 10, 2021, 593 participants (n=301 hIVIG, n=292 placebo) were enrolled at 63 sites in 11 countries; 579 patients were included in the mITT analysis. Compared with placebo, the hIVIG group did not have significantly greater odds of a more favourable outcome at day 7; the adjusted OR was 1·06 (95% CI 0·77–1·45; p=0·72). Infusions were well tolerated, although infusion reactions were more common in the hIVIG group (18·6% vs 9·5% for placebo; p=0·002). The percentage with the composite safety outcome at day 7 was similar for the hIVIG (24%) and placebo groups (25%; OR 0·98, 95% CI 0·66–1·46; p=0·91). The ORs for the day 7 ordinal outcome did not vary for subgroups considered, but there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome: risk was greater for hIVIG compared with placebo for patients who were antibody positive (OR 2·21, 95% CI 1·14–4·29); for patients who were antibody negative, the OR was 0·51 (0·29–0·90; pinteraction=0·001). INTERPRETATION: When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure. The safety of hIVIG might vary by the presence of endogenous neutralising antibodies at entry. FUNDING: US National Institutes of Health

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study

Purpose: Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical and virological disease trajectories. The purpose of this work was to identify risk factors associated with need for invasive mechanical ventilation (IMV), to analyse viral kinetics in patients with and without IMV and to provide a comprehensive description of clinical course. Methods: A cohort of 168 hospitalised adult COVID-19 patients enrolled in a prospective observational study at a large European tertiary care centre was analysed. Results: Forty-four per cent (71/161) of patients required invasive mechanical ventilation (IMV). Shorter duration of symptoms before admission (aOR 1.22 per day less, 95% CI 1.10-1.37, p < 0.01) and history of hypertension (aOR 5.55, 95% CI 2.00-16.82, p < 0.01) were associated with need for IMV. Patients on IMV had higher maximal concentrations, slower decline rates, and longer shedding of SARS-CoV-2 than non-IMV patients (33 days, IQR 26-46.75, vs 18 days, IQR 16-46.75, respectively, p < 0.01). Median duration of hospitalisation was 9 days (IQR 6-15.5) for non-IMV and 49.5 days (IQR 36.8-82.5) for IMV patients. Conclusions: Our results indicate a short duration of symptoms before admission as a risk factor for severe disease that merits further investigation and different viral load kinetics in severely affected patients. Median duration of hospitalisation of IMV patients was longer than described for acute respiratory distress syndrome unrelated to COVID-19